Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KROPHAN
- Development stage
- Unknown
- Lead developer
- Repha
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
KROPHAN is a dietary supplement developed by Repha GmbH Biologische Arzneimittel, primarily composed of bladderwrack (*Fucus vesiculosus*), a brown algae. It serves as a natural source of iodine, with each film-coated tablet providing 100 µg of iodine. The product is intended to support normal thyroid function and hormone production, particularly in individuals with increased iodine requirements, such as pregnant or nursing women. It is classified as a nutritional supplement (Nahrungsergänzungsmittel) rather than a pharmaceutical drug and is produced using ecologically sustainable wild harvesting methods that comply with European Pharmacopoeia standards.
- Brand names
- KROPHANKROPHAN Blasentangtabletten
- Other names
- BlasentangtablettenFucus vesiculosus tablets
Beyond the preview
Go deeper on KROPHAN.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KROPHAN.